Panel A: Systemic exposure to PEG-IFNα-2B in non human primates after the first subcutaneous administration.
Panel B: Systemic exposure to PEG-IFNα-2B in non human primates after the third subcutaneous administration (week 3 of treatment). 1, 2, 3: low dose, mid dose, high dose.
